array:24 [
  "pii" => "S2254887417300358"
  "issn" => "22548874"
  "doi" => "10.1016/j.rceng.2017.02.005"
  "estado" => "S300"
  "fechaPublicacion" => "2017-11-01"
  "aid" => "1375"
  "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)"
  "copyrightAnyo" => "2016"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "ssu"
  "cita" => "Rev Clin Esp. 2017;217:473-7"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 6
    "PDF" => 6
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0014256517300620"
      "issn" => "00142565"
      "doi" => "10.1016/j.rce.2017.02.007"
      "estado" => "S300"
      "fechaPublicacion" => "2017-11-01"
      "aid" => "1375"
      "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "ssu"
      "cita" => "Rev Clin Esp. 2017;217:473-7"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 105
        "formatos" => array:2 [
          "HTML" => 62
          "PDF" => 43
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">REVISI&#211;N</span>"
        "titulo" => "Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#58; hechos y promesas"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "473"
            "paginaFinal" => "477"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Cardiovascular safety of noninsulin antidiabetic drugs&#58; facts and promises"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "A&#46; Garc&#237;a-Lled&#243;, A&#46;M&#46; de Santiago-Nocito, F&#46;J&#46; de Abajo"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Garc&#237;a-Lled&#243;"
              ]
              1 => array:2 [
                "nombre" => "A&#46;M&#46;"
                "apellidos" => "de Santiago-Nocito"
              ]
              2 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "de Abajo"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2254887417300358"
          "doi" => "10.1016/j.rceng.2017.02.005"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300358?idApp=WRCEE"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517300620?idApp=WRCEE"
      "url" => "/00142565/0000021700000008/v1_201710301405/S0014256517300620/v1_201710301405/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2254887417300851"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.05.005"
    "estado" => "S300"
    "fechaPublicacion" => "2017-11-01"
    "aid" => "1402"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "ssu"
    "cita" => "Rev Clin Esp. 2017;217:478-83"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 5
      "PDF" => 5
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "Aortic stenosis&#46; Indications and results of percutaneous aortic valve implantation &#40;TAVI&#41;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "478"
          "paginaFinal" => "483"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Estenosis a&#243;rtica&#46; Indicaciones y resultados del implante de v&#225;lvula a&#243;rtica percut&#225;nea &#40;TAVI&#41;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 630
              "Ancho" => 2000
              "Tamanyo" => 210776
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Models of aortic percutaneous prostheses&#46;</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Edwards SAPIEN&#59; &#40;B&#41; Edwards SAPIEN XT&#59; &#40;C&#41; Edwards SAPIEN 3&#59; &#40;D&#41; Edwards Centera&#59; &#40;E&#41; Medtronic Core Valve&#59; &#40;F&#41; Medtronic Core Valve Evolut R&#59; &#40;G&#41; Medtronic Engager&#59; &#40;H&#41; Boston Lotus&#59; &#40;I&#41; Direct Flow Medical&#59; &#40;J&#41; St&#46; Jude Portico&#59; &#40;K&#41; Symetis Acurate&#59; &#40;L&#41; Jena Valve&#59; &#40;M&#41; Heart Leaflet Technologies&#59; &#40;N&#41; Colibri Heart Valve&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Salido Tahoces, R&#46;A&#46; Hern&#225;ndez Antol&#237;n, J&#46;L&#46; Zamorano G&#243;mez"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Salido Tahoces"
            ]
            1 => array:2 [
              "nombre" => "R&#46;A&#46;"
              "apellidos" => "Hern&#225;ndez Antol&#237;n"
            ]
            2 => array:2 [
              "nombre" => "J&#46;L&#46;"
              "apellidos" => "Zamorano G&#243;mez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301303"
        "doi" => "10.1016/j.rce.2017.05.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301303?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300851?idApp=WRCEE"
    "url" => "/22548874/0000021700000008/v1_201710301109/S2254887417300851/v1_201710301109/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2254887417300772"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.04.004"
    "estado" => "S300"
    "fechaPublicacion" => "2017-11-01"
    "aid" => "1400"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Rev Clin Esp. 2017;217:468-72"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 6
      "formatos" => array:2 [
        "HTML" => 1
        "PDF" => 5
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>"
      "titulo" => "HIV&#47;AIDS infection&#58; The beginning of the end for today&#39;s greatest pandemic&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "468"
          "paginaFinal" => "472"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Infecci&#243;n por el VIH&#47;sida&#58; &#191;El principio del fin de la primera gran pandemia contempor&#225;nea&#63;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "F&#46; Guti&#233;rrez"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Guti&#233;rrez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301285"
        "doi" => "10.1016/j.rce.2017.04.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301285?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300772?idApp=WRCEE"
    "url" => "/22548874/0000021700000008/v1_201710301109/S2254887417300772/v1_201710301109/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
    "titulo" => "Cardiovascular safety of noninsulin antidiabetic drugs&#58; Facts and promises"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "473"
        "paginaFinal" => "477"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "A&#46; Garc&#237;a-Lled&#243;, A&#46;M&#46; de Santiago-Nocito, F&#46;J&#46; de Abajo"
        "autores" => array:3 [
          0 => array:4 [
            "nombre" => "A&#46;"
            "apellidos" => "Garc&#237;a-Lled&#243;"
            "email" => array:1 [
              0 => "alberto&#46;garcia-lledo&#64;uah&#46;es"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "A&#46;M&#46;"
            "apellidos" => "de Santiago-Nocito"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "de Abajo"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:6 [
          0 => array:3 [
            "entidad" => "Servicio de Cardiolog&#237;a&#44; Hospital Universitario Pr&#237;ncipe de Asturias&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Medicina y Especialidades M&#233;dicas&#44; Facultad de Medicina y Ciencias de la Salud&#44; Universidad de Alcal&#225;&#44; Alcal&#225; de Henares&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "EAP Cogolludo&#44; Guadalajara&#44; SESCAM&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "C&#225;tedra SEMERGEN-Universidad de Alcal&#225;&#44; Alcal&#225; de Henares&#44; Madrid&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Unidad de Farmacolog&#237;a Cl&#237;nica&#44; Hospital Universitario Pr&#237;ncipe de Asturias&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Departamento de Ciencias Biom&#233;dicas&#44; Facultad de Medicina y Ciencias de la Salud&#44; Universidad de Alcal&#225;&#44; Alcal&#225; de Henares&#44; Madrid&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#58; hechos y promesas"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Background</span><p id="par0005" class="elsevierStylePara elsevierViewall">Type 2 diabetes mellitus &#40;DM2&#41; affects 13&#46;8&#37; of the population of Spain&#44; although 6&#46;8&#37; of those with DM2 are unaware of it&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">1</span></a> DM2&#39;s association with age&#44; physical inactivity and excess weight explains the increase in its prevalence&#46;<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">2</span></a> The microvascular damage makes DM2 the leading cause of blindness&#44; end-stage renal failure and&#44; due to the neuropathy&#44; nontraumatic leg amputation&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">3</span></a> The mortality of patients with diabetes is increasing&#44; with 60&#37; corresponding to cardiovascular causes&#46;<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">4&#44;5</span></a> Approximately 30&#37; of patients with stable or acute ischemic heart disease have DM2&#44;<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">6&#44;7</span></a> as well as a poorer outcome&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Surprisingly&#44; there are few noninsulin antidiabetic drugs &#40;NIAD&#41; that have been shown to reduce the cardiovascular risk &#40;CVR&#41;&#44; and there are questions about the safety of a number of NIADs&#46; For years&#44; it has been accepted that controlling blood glucose is beneficial in and of itself&#46; The alerts for drugs such as muraglitazar<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">8</span></a> and rosiglitazone<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">9</span></a> that&#44; while controlling blood glucose&#44; increase the CVR motivated the US Food and Drug Administration &#40;FDA&#41; to issue a directive requiring pharmaceutical companies to conduct cardiovascular safety studies with the new antidiabetic drugs &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">10</span></a> The directive required noninferiority studies with narrower statistical margins&#44; more patients&#44; longer study periods and the inclusion of patients with high CVR&#46; In the following 3 years&#44; the number of trials doubled&#44; and the number of patients included in these trials increased 6-fold&#46;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">11</span></a> The emerging results are creating enormous expectations but also some degree of controversy&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Trials with noninsulin antidiabetic drugs in type 2 diabetes mellitus</span><p id="par0030" class="elsevierStylePara elsevierViewall">In 1970&#44; the University Group Diabetes Program study was published&#44;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">12</span></a> the first randomized study on DM2 designed to demonstrate the usefulness of treating asymptomatic hyperglycemia&#46; The study included branches with insulin&#44; tolbutamide&#44; phenformin and placebo&#46; The study showed no overall benefit and suggested an increase in cardiovascular mortality in the sulfonylurea branch&#46; The study design was widely criticized&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">13</span></a> Nevertheless&#44; it has been shown that treatment with sulfonylureas blocks the myocardial adenosine triphosphate-sensitive K&#43; channels and impedes ischemic preconditioning in the long term&#44; a protective mechanism whose block would explain the excess mortality&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">14</span></a> These potential harmful effects have been supported by a Danish registry that included more than 100&#44;000 patients followed for up to 9 years&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">15</span></a> The registry showed an excess of total mortality&#44; cardiovascular mortality and ischemic events in the patients treated with glimepiride&#44; glibenclamide&#44; glipizide and tolbutamide&#44; compared with those treated with metformin&#44; although there were no differences in those treated with gliclazide or repaglinide&#46; The differences among the various sulfonylureas could be explained by the lower affinity for cardiac receptors of some of the sulfonylureas&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">13</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">In 1993&#44; the first 2 studies demonstrating the benefit of insulin in type 1 diabetes mellitus were published&#58; the Diabetes Control and Complications Trial<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">16</span></a> and the Stockholm Diabetes Intervention Study&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">17</span></a> There was a marked reduction in microvascular complications &#40;between 35&#37; and 75&#37;&#41;&#44; as well as a nonsignificant reduction in cardiovascular events in the Diabetes Control and Complications Trial&#46; Until the publication of the United Kingdom Prospective Diabetes Study in 1998&#44; the benefit of controlling hyperglycemia in DM2 had not been shown&#46;<a class="elsevierStyleCrossRefs" href="#bib0290"><span class="elsevierStyleSup">18&#44;19</span></a> The study included 5102 patients with recently diagnosed DM2&#44; who were followed for 10 years and who underwent treatment with insulin&#44; several sulfonylureas or metformin&#46; The study showed that a reduction in glycated hemoglobin &#40;HbA1c&#41; from 7&#46;9&#37; to 7&#37; was accompanied by a 25&#37; reduction in microvascular complications&#46; There was no significant reduction in macrovascular events&#44; but the analysis of the group treated with metformin showed a significant reduction &#40;39&#37;&#41; in the risk of death and infarction&#46; The follow-up of 3277 patients after 10 years of completing the study showed that the CVR benefit was maintained in the metformin-treated group and appeared significantly in the sulfonylurea and insulin group&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">20</span></a> These results reinforce the lasting benefit of early intervention and confirm the need for very long-term studies&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">In 2005&#44; the PROactive study was published&#44; which analyzed the potential cardiovascular benefit of pioglitazone &#40;a thiazolidinedione&#41; for 34 months&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">21</span></a> This study met the guidelines subsequently demanded by the FDA&#58; the 5238 patients had to have macrovascular disease&#46; A benefit for one of the primary composite endpoints could not be shown&#44; although a benefit was shown for the secondary composite endpoint of all-cause mortality&#44; nonfatal infarction and stroke&#46; Despite this benefit potential&#44; a significant increase was observed in nonfatal heart failure &#40;HF&#41;&#44; which could be related to the weight gain and edema observed in 5&#8211;15&#37; of the patients treated with thiazolidinediones&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">3</span></a> Various studies with rosiglitazone &#40;another thiazolidinedione&#41; planted serious questions about its safety&#46; The meta-analysis by Nissen et al&#46; showed an increased risk of infarction&#44; with a tendency to increased cardiovascular mortality due to cardiovascular causes&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">9</span></a> This outcome resulted in the withdrawal of the drug in Europe&#44; although not in the US&#44; possibly due to the results of the RECORD &#40;Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes&#41; study&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">22</span></a> The RECORD study randomized 4500 patients to rosiglitazone or a combination of metformin and sulfonylurea&#46; At 5&#46;5 years&#44; there were no differences in terms of cardiovascular events&#44; although rosiglitazone was associated with more hospitalizations for HF&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Research into drugs of the peroxisome proliferator-activated receptor &#40;&#945; and &#947;&#41; agonist family &#40;muraglitazar&#44; tesaglitazar and aleglitazar&#41; was suspended upon determining an increase in CVR in the phase 2 studies&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">8</span></a> The research on this drug family showed that the achievement of intermediate objectives&#44; such as good HbA1c control&#44; did not translate into a benefit in terms of survival and quality of life&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Studies have also been unable to demonstrate that the intensive reduction of blood glucose is a beneficial option&#46; In 2008&#44; the Action in Diabetes and Vascular Disease&#58; Preterax and Diamicron MR Controlled Evaluation &#40;ADVANCE&#41; study was published&#44; which compared cardiovascular events in 11&#44;140 patients treated with gliclazide to properly reach an HbA1c level between 7&#37; and 7&#46;9&#37; or below 6&#46;5&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">23</span></a> Although there was a reduction in diabetic nephropathy&#44; no effect was observed on macrovascular disease&#46; There was a greater risk of hypoglycemia in the intensive treatment group&#46; In 2010&#44; the Action to Control Cardiovascular Risk in Diabetes study had to be ended early due to an increase in mortality&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">24</span></a> The study had an even stricter objective in the intensive therapy group &#40;6&#37; of HbA1c vs&#46; a range of 7&#8211;7&#46;9&#37;&#41;&#46; The Veterans Affairs Diabetes Trial&#44; which had similar objectives&#44; also showed no benefit&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">25</span></a> Moreover&#44; various studies have demonstrated that the fundamental strategy for reducing the CVR of patients with DM2 is the comprehensive management of the other risk factors&#46;<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">26&#8211;30</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">In the years following the FDA directive&#44;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">10</span></a> studies have been published that shed light on the cardiovascular safety of 3 families of drugs&#58; dipeptidyl peptidase-4 inhibitors&#44; sodium-dependent glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Dipeptidyl peptidase-4 inhibitors reduce glucose levels by increasing insulin secretion and decreasing the secretion of glucose-dependent glucagon&#46; The group includes saxagliptin&#44; alogliptin&#44; and sitagliptin&#46; Their respective cardiovascular safety studies &#40;the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus &#91;SAVOR&#93;&#44;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">31</span></a> EXAMINE<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">32</span></a> and the Sitagliptin Cardiovascular Outcomes Study &#91;TECOS&#93;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">33</span></a>&#41; that included between 6000 and 16&#44;000 patients followed-up for 24&#8211;48 months showed their noninferiority in terms of reducing cardiovascular mortality&#44; infarction and stroke&#44; when compared with placebo&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Sodium-dependent glucose cotransporter 2 inhibitors reduce glucose reabsorption in the proximal renal tubules and decrease HbA1c levels&#44; blood pressure and weight&#44; with a low risk of hypoglycemia&#46; The group includes empagliflozine&#44; dapagliflozin and canagliflozin&#46; The Empagliflozin&#44; Cardiovascular Outcomes&#44; and Mortality in Type 2 Diabetes &#40;EMPA-REG-OUTCOME&#41; study<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">34</span></a> included 7020 patients randomized to 2 doses of empagliflozine or placebo&#44; with a mean follow-up of 3 years&#46; The drug significantly lowered all-cause death &#40;including cardiovascular&#41; and HF&#44; without affecting the infarction or stroke rates&#44; although there was a greater incidence of urinary tract infections&#46; The drug also showed a reduction in acute kidney injury and renal failure episodes&#46; Empagliflozine is the first NIAD that has shown a reduction in mortality&#44; although the patients in the EMPA-REG-OUTCOME study were frequently treated with other agents that reduced cardiovascular events&#44; such as statins and angiotensin-converting enzyme inhibitors&#46; A number of meta-analyses conducted with other drugs of this group have suggested a class effect&#44;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">35</span></a> which should be confirmed with safety studies for each of the drugs&#44; such as the Canagliflozin Cardiovascular Assessment Study&#44;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">36</span></a> which is still awaiting publication&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Glucagon-like peptide-1 receptor agonists are injectable drugs that increase insulin secretion and decrease the secretion of glucose-dependent glucagon&#46; These drugs increase satiety&#44; thereby promoting weight loss&#46; The group includes liraglutide and semaglutide&#46; The drugs are not available in the European Union&#44; and 2 studies have been published on their cardiovascular safety&#46; The Liraglutide Effect and Action in Diabetes&#58; Evaluation of Cardiovascular Outcome Results study included 9340 patients randomized to liraglutide or placebo&#44; with a follow-up of 3&#46;8 years&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">37</span></a> The study showed a significant reduction in total and cardiovascular mortality in the treatment group&#44; as well as a significant reduction in kidney damage&#44; with a tendency to decrease infarctions&#44; strokes and HF&#46; Another study&#44; the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes &#40;SUSTAIN-6&#41;&#44; included 3297 patients randomized to 2 doses of semaglutide or placebo&#44; with a follow-up of 2 years&#46;<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">38</span></a> In the treatment group&#44; there was no apparent reduction in death from cardiovascular causes or nonfatal infarction&#44; but there was a reduction in nonfatal stroke and nephropathy&#46; The use of semaglutide was associated with a significant increase in complicated retinopathy&#46; Lixisenatide &#40;another drug in the group&#41; did not lower the rate of recurrent events in patients with diabetes who had had a recent acute ischemic event&#46;<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">39</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Conclusions&#46; Future prospects</span><p id="par0175" class="elsevierStylePara elsevierViewall">From the above&#44; we can conclude the following&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1&#41;</span><p id="par0180" class="elsevierStylePara elsevierViewall">Despite the enormous repercussion of DM2&#44; studies designed to assess the benefit of NIADs for CVR are scarce&#44; and only the United Kingdom Prospective Diabetes Study&#44;<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">18</span></a> in its metformin branch&#44; has shown this benefit&#46; The most recent studies were safety studies and were designed to detect noninferiority&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">31&#8211;34&#44;36&#8211;38</span></a></p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2&#41;</span><p id="par0185" class="elsevierStylePara elsevierViewall">The available evidence indicates that the greatest reduction in CVR in DM2 is due to the use of statins and strict blood pressure control&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3&#41;</span><p id="par0190" class="elsevierStylePara elsevierViewall">Doubts remain about certain sulfonylureas &#40;glimepiride&#44; glibenclamide&#44; glipizide&#44; and tolbutamide&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">15</span></a> due to the lack of solid evidence on their cardiovascular benefit&#46; These doubts could influence research into new drugs&#44; if the new drugs are compared to drugs with dubious effect&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">40</span></a></p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4&#41;</span><p id="par0195" class="elsevierStylePara elsevierViewall">Empagliflozine&#44; liraglutide and semaglutide appear to reduce CVR&#44; a statement that should be prudent due to the following facts&#58; &#40;a&#41; studies are needed to demonstrate superiority in reducing cardiovascular events&#59; &#40;b&#41; we need to understand the mechanisms by which the benefits are produced and determine the potential class effects&#59; &#40;c&#41; follow-ups are still limited when we consider the disease&#39;s natural progression&#59; and &#40;d&#41; we need to demonstrate a benefit on microvascular disease&#46; Along these lines&#44; the possible deterioration in retinopathy observed with semaglutide should be analyzed in depth&#46;<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">38</span></a></p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5&#41;</span><p id="par0200" class="elsevierStylePara elsevierViewall">The residual risk for patients with DM2&#44; in other words&#44; the fact that they continue to experience events despite being adequately treated with available resources&#44; warrants long-term studies and drug combinations that&#44; as well as being safe&#44; provide various benefits&#46; Empagliflozine &#40;which lowered mortality and HF<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">34</span></a>&#41; and liraglutide &#40;which lowered myocardial infarction and stroke<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">37</span></a>&#41; could be examples&#46;</p></li></ul></p><p id="par0205" class="elsevierStylePara elsevierViewall">In any case&#44; these studies have repercussions on daily practice&#46; The first treatment step for DM2 should be metformin&#46; In light of the new evidence and until we have more solid data&#44; the second step should consist of the previously mentioned drugs that have demonstrated safety and a potential for benefits on survival&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Conflicts of interest</span><p id="par0210" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:9 [
        0 => array:3 [
          "identificador" => "xres932897"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec907305"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres932896"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec907304"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Background"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Trials with noninsulin antidiabetic drugs in type 2 diabetes mellitus"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Conclusions&#46; Future prospects"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Conflicts of interest"
        ]
        8 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2016-11-23"
    "fechaAceptado" => "2017-02-04"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec907305"
          "palabras" => array:3 [
            0 => "Diabetes mellitus"
            1 => "Cardiovascular risk"
            2 => "Oral diabetes drugs"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec907304"
          "palabras" => array:3 [
            0 => "Diabetes mellitus"
            1 => "Riesgo cardiovascular"
            2 => "Antidiab&#233;ticos orales"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Non insulin antidiabetic drugs are widely used in patients with type 2 diabetes&#46; However&#44; the drugs&#8217; effect in terms of reducing cardiovascular risk has been the subject of controversy&#46; In 2008&#44; based on the evidence of cardiovascular risk resulting from the use of a number of non insulin antidiabetic drugs&#44; the US Food and Drug Administration published directives on the need to perform cardiovascular safety studies&#46; These directives have helped obtain more evidence&#44; such that at present there are 2 families of drugs that can reduce cardiovascular risk&#46; These recent data have helped us add the reduction of cardiovascular morbidity and mortality to the objective of controlling blood glucose&#46; Nevertheless&#44; research continues with the development of new long-term studies&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Los antidiab&#233;ticos no insul&#237;nicos son f&#225;rmacos de uso muy extendido en los pacientes con diabetes tipo 2&#44; cuyo efecto sobre la reducci&#243;n del riesgo cardiovascular ha sido objeto de controversia&#46; En el a&#241;o 2008&#44; ante la evidencia del riesgo cardiovascular derivado del uso de algunos antidiab&#233;ticos no insul&#237;nicos&#44; la <span class="elsevierStyleItalic">Food and Drug Administration</span> americana public&#243; una directriz sobre la necesidad de realizar estudios de seguridad cardiovascular&#46; Ello ha contribuido a disponer de m&#225;s evidencia&#44; de manera que en el momento actual existen dos familias de f&#225;rmacos que podr&#237;an reducir el riesgo cardiovascular&#46; Estos datos recientes nos permiten a&#241;adir&#44; al objetivo de controlar la glucemia&#44; el de reducir la morbimortalidad cardiovascular&#46; No obstante&#44; la investigaci&#243;n contin&#250;a con el desarrollo de nuevos estudios a largo plazo&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Garc&#237;a-Lled&#243; A&#44; de Santiago-Nocito AM&#44; de Abajo FJ&#46; Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#58; hechos y promesas&#46; Rev Clin Esp&#46; 2017&#59;217&#58;473&#8211;477&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Source</span>&#58; U&#46;S&#46; Department of Health and Human Services&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">10</span></a></p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">For studies with new designs</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>For phase 2 and 3 studies&#44; there should be an independent prospective adjudication committee for cardiovascular events&#46; The minimum cardiovascular events to be recorded are defined&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Phase 2 and 3 studies should include patients with high cardiovascular risk&#44; long-standing diabetes&#44; advanced age and kidney damage&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>A longer duration is proposed for safety studies &#40;at least 2 years&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Phase 2 and 3 studies should be designed to facilitate their subsequent inclusion in a meta-analysis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The sponsors should deliver a protocol that describes the statistical methods of the proposed meta-analyses&#46; Recommendations are made on the types of studies and identifiers for variables to be included&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The differences and similarities of the events by subgroup should be examined&#44; when possible&#44; indicating as examples sex&#44; race and age&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">For completed studies&#44; before submitting them for evaluation</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The statistical margins for the confidence interval are narrowed in the noninferiority studies regarding cardiovascular events&#46; When it is not possible to demonstrate them with meta-analyses&#44; new studies should be performed&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>If the premarketing request shows clinical data outside the previous demands but within less demanding predefined ranges and the overall risk&#8211;benefit analysis supports the approval of the drug&#44; a specific study may be requested to demonstrate the safety adjusted to the new required limits&#44; once the drug has been marketed&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The characteristics these studies must have for their evaluation and inclusion in meta-analyses are defined&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1576665.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Summary of the food and drug administration directives for the assessment of cardiovascular risk in new antidiabetic therapies&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:40 [
            0 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalence of diabetes mellitus and impaired glucose regulation in Spain&#58; the Di&#64;bet&#46;es Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Soriguer"
                            1 => "A&#46; Goday"
                            2 => "A&#46; Bosch-Comas"
                            3 => "E&#46; Bordi&#250;"
                            4 => "A&#46; Calle-Pascual"
                            5 => "R&#46; Carmena"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00125-011-2336-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetologia"
                        "fecha" => "2012"
                        "volumen" => "55"
                        "paginaInicial" => "88"
                        "paginaFinal" => "93"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21987347"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global prevalence of diabetes&#46; Estimates for the year 2000 and projections for 2030"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46; Wild"
                            1 => "G&#46; Roglic"
                            2 => "A&#46; Green"
                            3 => "R&#46; Sicree"
                            4 => "H&#46; King"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetes Care"
                        "fecha" => "2004"
                        "volumen" => "27"
                        "paginaInicial" => "1047"
                        "paginaFinal" => "1053"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15111519"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#46; Posicionamiento cient&#237;fico Semergen"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;A&#46; Prieto"
                            1 => "J&#46;M&#46; Comas-Samper"
                            2 => "C&#46; Escobar-Cervantes"
                            3 => "V&#46; Gasull-Molinera"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semerg.2014.04.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semergen"
                        "fecha" => "2014"
                        "volumen" => "40"
                        "paginaInicial" => "261"
                        "paginaFinal" => "273"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24882393"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diabetes mellitus&#44; fasting glucose&#44; and risk of cause-specific death"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;R&#46; Seshasai"
                            1 => "S&#46; Kaptoge"
                            2 => "A&#46; Thompson"
                            3 => "E&#46; di Angelantonio"
                            4 => "P&#46; Gao"
                            5 => "N&#46; Sarwar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1008862"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "364"
                        "paginaInicial" => "829"
                        "paginaFinal" => "841"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21366474"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relaciones epidemiol&#243;gicas de la enfermedad arterioscler&#243;tica entre los diferentes territorios vasculares"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "W&#46;B&#46; Kannel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:5 [
                        "titulo" => "Aterosclerosis y enfermedad coronaria"
                        "paginaInicial" => "1691"
                        "paginaFinal" => "1698"
                        "edicion" => "1&#46;&#170; ed"
                        "serieFecha" => "1997"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalencia de angina estable en Espa&#241;a&#46; Resultados del estudio OFRECE"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Alonso"
                            1 => "J&#46; Mu&#241;iz"
                            2 => "J&#46;J&#46; G&#243;mez-Doblas"
                            3 => "G&#46; Rodr&#237;guez-Roca"
                            4 => "J&#46;M&#46; Lobos"
                            5 => "G&#46; Permanyer-Miralda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rec.2014.09.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Esp Cardiol"
                        "fecha" => "2015"
                        "volumen" => "68"
                        "paginaInicial" => "691"
                        "paginaFinal" => "699"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25697076"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acute myocardial infarction in diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46;W&#46; Nesto"
                            1 => "S&#46; Zarich"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "1998"
                        "volumen" => "97"
                        "paginaInicial" => "12"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9443424"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46; Nissen"
                            1 => "K&#46; Wolsky"
                            2 => "E&#46;J&#46; Topol"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.294.20.joc50147"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2005"
                        "volumen" => "294"
                        "paginaInicial" => "2581"
                        "paginaFinal" => "2586"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16239637"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46; Nissen"
                            1 => "K&#46; Wolsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa072761"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2007"
                        "volumen" => "356"
                        "paginaInicial" => "2457"
                        "paginaFinal" => "2471"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17517853"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "U&#46;S&#46; Department of Health and Human Services&#46; Food and Drug Administration&#46; Center for Drug Evaluation and Research &#40;CDER&#41;&#46; Guidance for Industry Diabetes Mellitus&#46; Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 Diabetes&#46; December 2008&#46; &#91;consulted 12 Nov 2016&#93;&#46; http&#58;&#47;&#47;www&#46;fda&#46;gov&#47;downloads&#47;drugs&#47;guidancecomplianceregulatoryinformation&#47;guidances&#47;ucm071627&#46;pdf&#46;"
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of FDA guidance for developing diabetes drugs on trial design&#58; from policy to practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;A&#46; Bethel"
                            1 => "H&#46; Sourij"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11886-011-0229-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Cardiol Rep"
                        "fecha" => "2012"
                        "volumen" => "14"
                        "paginaInicial" => "59"
                        "paginaFinal" => "69"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22094711"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes&#58; II&#46; Mortality results"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "University Group Diabetes Program Research Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Diabetes"
                        "fecha" => "1970"
                        "volumen" => "19"
                        "paginaInicial" => "785"
                        "paginaFinal" => "830"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The UGDP controversy&#58; thirty-four years of contentious ambiguity laid to rest"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "T&#46;B&#46; Schwartz"
                            1 => "C&#46;L&#46; Meinert"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Perspect Biol Med"
                        "fecha" => "2004"
                        "volumen" => "47"
                        "paginaInicial" => "564"
                        "paginaFinal" => "574"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15467178"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium&#46; Two paradoxes revisited"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46;C&#46; Cleveland Jr&#46;"
                            1 => "D&#46;R&#46; Meldrum"
                            2 => "B&#46;S&#46; Cain"
                            3 => "A&#46; Banerjee"
                            4 => "A&#46;H&#46; Harken"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "1997"
                        "volumen" => "96"
                        "paginaInicial" => "29"
                        "paginaFinal" => "32"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9236412"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes&#44; with or without a previous myocardial infarction&#58; a nationwide study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;K&#46; Schramm"
                            1 => "G&#46;H&#46; Gislason"
                            2 => "A&#46; Vaag"
                            3 => "J&#46;N&#46; Rasmussen"
                            4 => "F&#46; Folke"
                            5 => "M&#46;L&#46; Hansen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehr077"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2011"
                        "volumen" => "32"
                        "paginaInicial" => "1900"
                        "paginaFinal" => "1908"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21471135"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "Diabetes Control&#44; Complications Trial Research Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM199309303291401"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1993"
                        "volumen" => "329"
                        "paginaInicial" => "977"
                        "paginaFinal" => "986"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8366922"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "P&#46; Reichard"
                            1 => "B&#46;Y&#46; Nilsson"
                            2 => "V&#46; Rosenqvist"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM199307293290502"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1993"
                        "volumen" => "329"
                        "paginaInicial" => "304"
                        "paginaFinal" => "309"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8147960"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "UK Prospective Diabetes Study Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "1998"
                        "volumen" => "352"
                        "paginaInicial" => "837"
                        "paginaFinal" => "853"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9742976"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of intensive blood glucose control policy with metformin on complications in type 2 diabetes patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "UK Prospective Diabetes Study Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "1998"
                        "volumen" => "352"
                        "paginaInicial" => "854"
                        "paginaFinal" => "865"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9742977"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "10-Year follow-up of intensive glucose control in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Colman"
                            1 => "S&#46;K&#46; Paul"
                            2 => "M&#46;A&#46; Bethel"
                            3 => "D&#46;R&#46; Matthews"
                            4 => "H&#46;A&#46; Neil"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0806470"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "359"
                        "paginaInicial" => "1577"
                        "paginaFinal" => "1589"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18784090"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "PROactive investigators&#46; Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study &#40;PROspective pioglitAzone Clinical Trial in macro-Vascular Events&#41;&#58; a randomised controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;A&#46; Dormandy"
                            1 => "B&#46; Charbonnel"
                            2 => "D&#46;J&#46; Eckland"
                            3 => "E&#46; Erdmann"
                            4 => "M&#46; Massi-Benedetti"
                            5 => "I&#46;K&#46; Moules"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(05)67528-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2005"
                        "volumen" => "366"
                        "paginaInicial" => "1279"
                        "paginaFinal" => "1289"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16214598"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes &#40;RECORD&#41;&#58; a multicentre&#44; randomised&#44; open-label trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46;D&#46; Home"
                            1 => "S&#46;J&#46; Pocock"
                            2 => "H&#46; Beck-Nielsen"
                            3 => "P&#46;S&#46; Curtis"
                            4 => "R&#46; Gomis"
                            5 => "M&#46; Hanefeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(09)60953-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2009"
                        "volumen" => "373"
                        "paginaInicial" => "2125"
                        "paginaFinal" => "2135"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19501900"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Patel"
                            1 => "S&#46; MacMahon"
                            2 => "J&#46; Chalmers"
                            3 => "B&#46; Neal"
                            4 => "L&#46; Billot"
                            5 => "M&#46; Woodward"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0802987"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "2560"
                        "paginaFinal" => "2572"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18539916"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of intensive glucose lowering in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;C&#46; Gerstein"
                            1 => "M&#46;E&#46; Miller"
                            2 => "R&#46;P&#46; Byington"
                            3 => "D&#46;C&#46; Goff Jr&#46;"
                            4 => "J&#46;T&#46; Bigger"
                            5 => "J&#46;B&#46; Buse"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0802743"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "2545"
                        "paginaFinal" => "2559"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18539917"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Glucose control and vascular complications in veterans with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "W&#46; Duckworth"
                            1 => "C&#46; Abraira"
                            2 => "T&#46; Moritz"
                            3 => "D&#46; Reda"
                            4 => "N&#46; Emanuele"
                            5 => "P&#46; Reaven"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0808431"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2009"
                        "volumen" => "360"
                        "paginaInicial" => "129"
                        "paginaFinal" => "139"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19092145"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of a multifactorial intervention on mortality in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "P&#46; Gaede"
                            1 => "H&#46; Lund-Andersen"
                            2 => "H&#46;H&#46; Parving"
                            3 => "O&#46; Pedersen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0706245"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "580"
                        "paginaFinal" => "591"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18256393"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study &#40;CARDS&#41;&#58; multicentre randomised placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;M&#46; Colhoun"
                            1 => "D&#46;J&#46; Betteridge"
                            2 => "P&#46;N&#46; Durrington"
                            3 => "G&#46;A&#46; Hitman"
                            4 => "H&#46;A&#46; Neil"
                            5 => "S&#46;J&#46; Livingstone"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(04)16895-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2004"
                        "volumen" => "364"
                        "paginaInicial" => "685"
                        "paginaFinal" => "696"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15325833"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of cholesterol-lowering treatment&#58; prospective meta-analysis of data from 90&#44;056 participants in 14 randomised trials of statins"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Baigent"
                            1 => "A&#46; Keech"
                            2 => "P&#46;M&#46; Kearney"
                            3 => "L&#46; Blackwell"
                            4 => "G&#46; Buck"
                            5 => "C&#46; Pollicino"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(05)67394-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2005"
                        "volumen" => "366"
                        "paginaInicial" => "1267"
                        "paginaFinal" => "1278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16214597"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Blood pressure lowering in type 2 diabetes&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C&#46;A&#46; Emdin"
                            1 => "K&#46; Rahimi"
                            2 => "B&#46; Neal"
                            3 => "T&#46; Callender"
                            4 => "V&#46; Perkovic"
                            5 => "A&#46; Patel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.2014.18574"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2015"
                        "volumen" => "313"
                        "paginaInicial" => "603"
                        "paginaFinal" => "615"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25668264"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "European Guidelines on cardiovascular disease prevention in clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "The sixth joint task force of the European Society of Cardiology&#44; other societies on cardiovascular disease prevention in clinical practice"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehw106"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2016"
                        "volumen" => "37"
                        "paginaInicial" => "2315"
                        "paginaFinal" => "2323"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27222591"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "SAVOR-TIMI 53 Steering Committee and Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46;M&#46; Scirica"
                            1 => "D&#46;L&#46; Bhatt"
                            2 => "E&#46; Braunwald"
                            3 => "P&#46;G&#46; Steg"
                            4 => "J&#46; Davidson"
                            5 => "B&#46; Hirshberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1307684"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "369"
                        "paginaInicial" => "1317"
                        "paginaFinal" => "1326"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23992601"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alogliptin after acute coronary syndrome in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "EXAMINE Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "W&#46;B&#46; White"
                            1 => "C&#46;P&#46; Cannon"
                            2 => "S&#46;R&#46; Heller"
                            3 => "S&#46;E&#46; Nissen"
                            4 => "R&#46;M&#46; Bergenstal"
                            5 => "G&#46;L&#46; Bakris"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1305889"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "369"
                        "paginaInicial" => "1327"
                        "paginaFinal" => "1335"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23992602"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;B&#46; Green"
                            1 => "M&#46;A&#46; Bethel"
                            2 => "P&#46;W&#46; Armstrong"
                            3 => "J&#46;B&#46; Buse"
                            4 => "S&#46;S&#46; Engel"
                            5 => "J&#46; Garg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1501352"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "232"
                        "paginaFinal" => "242"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26052984"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Empagliflozin&#44; cardiovascular outcomes&#44; and mortality in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "EMPA-REG OUTCOME Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Zinman"
                            1 => "C&#46; Wanner"
                            2 => "J&#46;M&#46; Lachin"
                            3 => "D&#46; Fitchett"
                            4 => "E&#46; Bluhmki"
                            5 => "S&#46; Hantel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "2117"
                        "paginaFinal" => "2128"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of SGLT-2 inhibitors on mortality and cardiovascular events&#58; a comprehensive meta-analysis of randomized controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46; Monami"
                            1 => "I&#46; Dicembrini"
                            2 => "E&#46; Mannucci"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00592-016-0892-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Diabetol"
                        "fecha" => "2017"
                        "volumen" => "54"
                        "paginaInicial" => "19"
                        "paginaFinal" => "36"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27488726"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rationale&#44; design&#44; and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study &#40;CANVAS&#41;&#58; a randomized placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Neal"
                            1 => "V&#46; Perkovic"
                            2 => "D&#46; de Zeeuw"
                            3 => "K&#46;W&#46; Mahaffey"
                            4 => "G&#46; Fulcher"
                            5 => "P&#46; Stein"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ahj.2013.05.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am Heart J"
                        "fecha" => "2013"
                        "volumen" => "166"
                        "paginaInicial" => "217"
                        "paginaFinal" => "223"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23895803"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Liraglutide and cardiovascular outcomes in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;P&#46; Marso"
                            1 => "G&#46;H&#46; Daniels"
                            2 => "K&#46; Brown-Frandsen"
                            3 => "P&#46; Kristensen"
                            4 => "J&#46;F&#46; Mann"
                            5 => "M&#46;A&#46; Nauck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1603827"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2016"
                        "volumen" => "375"
                        "paginaInicial" => "311"
                        "paginaFinal" => "322"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27295427"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;P&#46; Marso"
                            1 => "S&#46;C&#46; Bain"
                            2 => "A&#46; Consoli"
                            3 => "F&#46;G&#46; Eliaschewitz"
                            4 => "E&#46; J&#243;dar"
                            5 => "L&#46;A&#46; Leiter"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1607141"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2016"
                        "volumen" => "375"
                        "paginaInicial" => "1834"
                        "paginaFinal" => "1844"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27633186"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lixisenatide in patients with type 2 diabetes and acute coronary s&#237;ndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;A&#46; Pfeffer"
                            1 => "B&#46; Claggett"
                            2 => "R&#46; Diaz"
                            3 => "K&#46; Dickstein"
                            4 => "H&#46;C&#46; Gerstein"
                            5 => "L&#46;V&#46; K&#248;ber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1509225"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "2247"
                        "paginaFinal" => "2257"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26630143"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone&#58; impact on cardiovascular events&#46; A randomized controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "O&#46; Vaccaro"
                            1 => "M&#46; Masulli"
                            2 => "E&#46; Bonora"
                            3 => "S&#46; Del Prato"
                            4 => "C&#46;B&#46; Giorda"
                            5 => "A&#46;P&#46; Maggioni"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.numecd.2012.09.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nutr Metab Cardiovasc Dis"
                        "fecha" => "2012"
                        "volumen" => "22"
                        "paginaInicial" => "997"
                        "paginaFinal" => "1006"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23063367"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/22548874/0000021700000008/v1_201710301109/S2254887417300358/v1_201710301109/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "48740"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Reviews"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/22548874/0000021700000008/v1_201710301109/S2254887417300358/v1_201710301109/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300358?idApp=WRCEE"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Review
Cardiovascular safety of noninsulin antidiabetic drugs: Facts and promises
Seguridad cardiovascular de los antidiabéticos no insulínicos: hechos y promesas
A. García-Lledóa,b,
Corresponding author
alberto.garcia-lledo@uah.es

Corresponding author.
, A.M. de Santiago-Nocitoc,d, F.J. de Abajoe,f
a Servicio de Cardiología, Hospital Universitario Príncipe de Asturias, Spain
b Departamento de Medicina y Especialidades Médicas, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
c EAP Cogolludo, Guadalajara, SESCAM, Spain
d Cátedra SEMERGEN-Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
e Unidad de Farmacología Clínica, Hospital Universitario Príncipe de Asturias, Spain
f Departamento de Ciencias Biomédicas, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
Read
13
Times
was read the article
10
Total PDF
3
Total HTML
Share statistics
 array:24 [
  "pii" => "S2254887417300358"
  "issn" => "22548874"
  "doi" => "10.1016/j.rceng.2017.02.005"
  "estado" => "S300"
  "fechaPublicacion" => "2017-11-01"
  "aid" => "1375"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
  "copyrightAnyo" => "2016"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "ssu"
  "cita" => "Rev Clin Esp. 2017;217:473-7"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 6
    "PDF" => 6
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0014256517300620"
      "issn" => "00142565"
      "doi" => "10.1016/j.rce.2017.02.007"
      "estado" => "S300"
      "fechaPublicacion" => "2017-11-01"
      "aid" => "1375"
      "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "ssu"
      "cita" => "Rev Clin Esp. 2017;217:473-7"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:2 [
        "total" => 105
        "formatos" => array:2 [
          "HTML" => 62
          "PDF" => 43
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">REVISI&#211;N</span>"
        "titulo" => "Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#58; hechos y promesas"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "473"
            "paginaFinal" => "477"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Cardiovascular safety of noninsulin antidiabetic drugs&#58; facts and promises"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "A&#46; Garc&#237;a-Lled&#243;, A&#46;M&#46; de Santiago-Nocito, F&#46;J&#46; de Abajo"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Garc&#237;a-Lled&#243;"
              ]
              1 => array:2 [
                "nombre" => "A&#46;M&#46;"
                "apellidos" => "de Santiago-Nocito"
              ]
              2 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "de Abajo"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2254887417300358"
          "doi" => "10.1016/j.rceng.2017.02.005"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300358?idApp=WRCEE"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517300620?idApp=WRCEE"
      "url" => "/00142565/0000021700000008/v1_201710301405/S0014256517300620/v1_201710301405/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2254887417300851"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.05.005"
    "estado" => "S300"
    "fechaPublicacion" => "2017-11-01"
    "aid" => "1402"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "ssu"
    "cita" => "Rev Clin Esp. 2017;217:478-83"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 5
      "PDF" => 5
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "Aortic stenosis&#46; Indications and results of percutaneous aortic valve implantation &#40;TAVI&#41;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "478"
          "paginaFinal" => "483"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Estenosis a&#243;rtica&#46; Indicaciones y resultados del implante de v&#225;lvula a&#243;rtica percut&#225;nea &#40;TAVI&#41;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 630
              "Ancho" => 2000
              "Tamanyo" => 210776
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Models of aortic percutaneous prostheses&#46;</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Edwards SAPIEN&#59; &#40;B&#41; Edwards SAPIEN XT&#59; &#40;C&#41; Edwards SAPIEN 3&#59; &#40;D&#41; Edwards Centera&#59; &#40;E&#41; Medtronic Core Valve&#59; &#40;F&#41; Medtronic Core Valve Evolut R&#59; &#40;G&#41; Medtronic Engager&#59; &#40;H&#41; Boston Lotus&#59; &#40;I&#41; Direct Flow Medical&#59; &#40;J&#41; St&#46; Jude Portico&#59; &#40;K&#41; Symetis Acurate&#59; &#40;L&#41; Jena Valve&#59; &#40;M&#41; Heart Leaflet Technologies&#59; &#40;N&#41; Colibri Heart Valve&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Salido Tahoces, R&#46;A&#46; Hern&#225;ndez Antol&#237;n, J&#46;L&#46; Zamorano G&#243;mez"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Salido Tahoces"
            ]
            1 => array:2 [
              "nombre" => "R&#46;A&#46;"
              "apellidos" => "Hern&#225;ndez Antol&#237;n"
            ]
            2 => array:2 [
              "nombre" => "J&#46;L&#46;"
              "apellidos" => "Zamorano G&#243;mez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301303"
        "doi" => "10.1016/j.rce.2017.05.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301303?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300851?idApp=WRCEE"
    "url" => "/22548874/0000021700000008/v1_201710301109/S2254887417300851/v1_201710301109/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2254887417300772"
    "issn" => "22548874"
    "doi" => "10.1016/j.rceng.2017.04.004"
    "estado" => "S300"
    "fechaPublicacion" => "2017-11-01"
    "aid" => "1400"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Medicina Interna &#40;SEMI&#41;"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Rev Clin Esp. 2017;217:468-72"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 6
      "formatos" => array:2 [
        "HTML" => 1
        "PDF" => 5
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>"
      "titulo" => "HIV&#47;AIDS infection&#58; The beginning of the end for today&#39;s greatest pandemic&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "468"
          "paginaFinal" => "472"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Infecci&#243;n por el VIH&#47;sida&#58; &#191;El principio del fin de la primera gran pandemia contempor&#225;nea&#63;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "F&#46; Guti&#233;rrez"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Guti&#233;rrez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0014256517301285"
        "doi" => "10.1016/j.rce.2017.04.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256517301285?idApp=WRCEE"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300772?idApp=WRCEE"
    "url" => "/22548874/0000021700000008/v1_201710301109/S2254887417300772/v1_201710301109/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
    "titulo" => "Cardiovascular safety of noninsulin antidiabetic drugs&#58; Facts and promises"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "473"
        "paginaFinal" => "477"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "A&#46; Garc&#237;a-Lled&#243;, A&#46;M&#46; de Santiago-Nocito, F&#46;J&#46; de Abajo"
        "autores" => array:3 [
          0 => array:4 [
            "nombre" => "A&#46;"
            "apellidos" => "Garc&#237;a-Lled&#243;"
            "email" => array:1 [
              0 => "alberto&#46;garcia-lledo&#64;uah&#46;es"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "A&#46;M&#46;"
            "apellidos" => "de Santiago-Nocito"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "de Abajo"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:6 [
          0 => array:3 [
            "entidad" => "Servicio de Cardiolog&#237;a&#44; Hospital Universitario Pr&#237;ncipe de Asturias&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Medicina y Especialidades M&#233;dicas&#44; Facultad de Medicina y Ciencias de la Salud&#44; Universidad de Alcal&#225;&#44; Alcal&#225; de Henares&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "EAP Cogolludo&#44; Guadalajara&#44; SESCAM&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "C&#225;tedra SEMERGEN-Universidad de Alcal&#225;&#44; Alcal&#225; de Henares&#44; Madrid&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Unidad de Farmacolog&#237;a Cl&#237;nica&#44; Hospital Universitario Pr&#237;ncipe de Asturias&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Departamento de Ciencias Biom&#233;dicas&#44; Facultad de Medicina y Ciencias de la Salud&#44; Universidad de Alcal&#225;&#44; Alcal&#225; de Henares&#44; Madrid&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#58; hechos y promesas"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Background</span><p id="par0005" class="elsevierStylePara elsevierViewall">Type 2 diabetes mellitus &#40;DM2&#41; affects 13&#46;8&#37; of the population of Spain&#44; although 6&#46;8&#37; of those with DM2 are unaware of it&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">1</span></a> DM2&#39;s association with age&#44; physical inactivity and excess weight explains the increase in its prevalence&#46;<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">2</span></a> The microvascular damage makes DM2 the leading cause of blindness&#44; end-stage renal failure and&#44; due to the neuropathy&#44; nontraumatic leg amputation&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">3</span></a> The mortality of patients with diabetes is increasing&#44; with 60&#37; corresponding to cardiovascular causes&#46;<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">4&#44;5</span></a> Approximately 30&#37; of patients with stable or acute ischemic heart disease have DM2&#44;<a class="elsevierStyleCrossRefs" href="#bib0230"><span class="elsevierStyleSup">6&#44;7</span></a> as well as a poorer outcome&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Surprisingly&#44; there are few noninsulin antidiabetic drugs &#40;NIAD&#41; that have been shown to reduce the cardiovascular risk &#40;CVR&#41;&#44; and there are questions about the safety of a number of NIADs&#46; For years&#44; it has been accepted that controlling blood glucose is beneficial in and of itself&#46; The alerts for drugs such as muraglitazar<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">8</span></a> and rosiglitazone<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">9</span></a> that&#44; while controlling blood glucose&#44; increase the CVR motivated the US Food and Drug Administration &#40;FDA&#41; to issue a directive requiring pharmaceutical companies to conduct cardiovascular safety studies with the new antidiabetic drugs &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">10</span></a> The directive required noninferiority studies with narrower statistical margins&#44; more patients&#44; longer study periods and the inclusion of patients with high CVR&#46; In the following 3 years&#44; the number of trials doubled&#44; and the number of patients included in these trials increased 6-fold&#46;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">11</span></a> The emerging results are creating enormous expectations but also some degree of controversy&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Trials with noninsulin antidiabetic drugs in type 2 diabetes mellitus</span><p id="par0030" class="elsevierStylePara elsevierViewall">In 1970&#44; the University Group Diabetes Program study was published&#44;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">12</span></a> the first randomized study on DM2 designed to demonstrate the usefulness of treating asymptomatic hyperglycemia&#46; The study included branches with insulin&#44; tolbutamide&#44; phenformin and placebo&#46; The study showed no overall benefit and suggested an increase in cardiovascular mortality in the sulfonylurea branch&#46; The study design was widely criticized&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">13</span></a> Nevertheless&#44; it has been shown that treatment with sulfonylureas blocks the myocardial adenosine triphosphate-sensitive K&#43; channels and impedes ischemic preconditioning in the long term&#44; a protective mechanism whose block would explain the excess mortality&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">14</span></a> These potential harmful effects have been supported by a Danish registry that included more than 100&#44;000 patients followed for up to 9 years&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">15</span></a> The registry showed an excess of total mortality&#44; cardiovascular mortality and ischemic events in the patients treated with glimepiride&#44; glibenclamide&#44; glipizide and tolbutamide&#44; compared with those treated with metformin&#44; although there were no differences in those treated with gliclazide or repaglinide&#46; The differences among the various sulfonylureas could be explained by the lower affinity for cardiac receptors of some of the sulfonylureas&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">13</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">In 1993&#44; the first 2 studies demonstrating the benefit of insulin in type 1 diabetes mellitus were published&#58; the Diabetes Control and Complications Trial<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">16</span></a> and the Stockholm Diabetes Intervention Study&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">17</span></a> There was a marked reduction in microvascular complications &#40;between 35&#37; and 75&#37;&#41;&#44; as well as a nonsignificant reduction in cardiovascular events in the Diabetes Control and Complications Trial&#46; Until the publication of the United Kingdom Prospective Diabetes Study in 1998&#44; the benefit of controlling hyperglycemia in DM2 had not been shown&#46;<a class="elsevierStyleCrossRefs" href="#bib0290"><span class="elsevierStyleSup">18&#44;19</span></a> The study included 5102 patients with recently diagnosed DM2&#44; who were followed for 10 years and who underwent treatment with insulin&#44; several sulfonylureas or metformin&#46; The study showed that a reduction in glycated hemoglobin &#40;HbA1c&#41; from 7&#46;9&#37; to 7&#37; was accompanied by a 25&#37; reduction in microvascular complications&#46; There was no significant reduction in macrovascular events&#44; but the analysis of the group treated with metformin showed a significant reduction &#40;39&#37;&#41; in the risk of death and infarction&#46; The follow-up of 3277 patients after 10 years of completing the study showed that the CVR benefit was maintained in the metformin-treated group and appeared significantly in the sulfonylurea and insulin group&#46;<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">20</span></a> These results reinforce the lasting benefit of early intervention and confirm the need for very long-term studies&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">In 2005&#44; the PROactive study was published&#44; which analyzed the potential cardiovascular benefit of pioglitazone &#40;a thiazolidinedione&#41; for 34 months&#46;<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">21</span></a> This study met the guidelines subsequently demanded by the FDA&#58; the 5238 patients had to have macrovascular disease&#46; A benefit for one of the primary composite endpoints could not be shown&#44; although a benefit was shown for the secondary composite endpoint of all-cause mortality&#44; nonfatal infarction and stroke&#46; Despite this benefit potential&#44; a significant increase was observed in nonfatal heart failure &#40;HF&#41;&#44; which could be related to the weight gain and edema observed in 5&#8211;15&#37; of the patients treated with thiazolidinediones&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">3</span></a> Various studies with rosiglitazone &#40;another thiazolidinedione&#41; planted serious questions about its safety&#46; The meta-analysis by Nissen et al&#46; showed an increased risk of infarction&#44; with a tendency to increased cardiovascular mortality due to cardiovascular causes&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">9</span></a> This outcome resulted in the withdrawal of the drug in Europe&#44; although not in the US&#44; possibly due to the results of the RECORD &#40;Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes&#41; study&#46;<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">22</span></a> The RECORD study randomized 4500 patients to rosiglitazone or a combination of metformin and sulfonylurea&#46; At 5&#46;5 years&#44; there were no differences in terms of cardiovascular events&#44; although rosiglitazone was associated with more hospitalizations for HF&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Research into drugs of the peroxisome proliferator-activated receptor &#40;&#945; and &#947;&#41; agonist family &#40;muraglitazar&#44; tesaglitazar and aleglitazar&#41; was suspended upon determining an increase in CVR in the phase 2 studies&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">8</span></a> The research on this drug family showed that the achievement of intermediate objectives&#44; such as good HbA1c control&#44; did not translate into a benefit in terms of survival and quality of life&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Studies have also been unable to demonstrate that the intensive reduction of blood glucose is a beneficial option&#46; In 2008&#44; the Action in Diabetes and Vascular Disease&#58; Preterax and Diamicron MR Controlled Evaluation &#40;ADVANCE&#41; study was published&#44; which compared cardiovascular events in 11&#44;140 patients treated with gliclazide to properly reach an HbA1c level between 7&#37; and 7&#46;9&#37; or below 6&#46;5&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">23</span></a> Although there was a reduction in diabetic nephropathy&#44; no effect was observed on macrovascular disease&#46; There was a greater risk of hypoglycemia in the intensive treatment group&#46; In 2010&#44; the Action to Control Cardiovascular Risk in Diabetes study had to be ended early due to an increase in mortality&#46;<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">24</span></a> The study had an even stricter objective in the intensive therapy group &#40;6&#37; of HbA1c vs&#46; a range of 7&#8211;7&#46;9&#37;&#41;&#46; The Veterans Affairs Diabetes Trial&#44; which had similar objectives&#44; also showed no benefit&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">25</span></a> Moreover&#44; various studies have demonstrated that the fundamental strategy for reducing the CVR of patients with DM2 is the comprehensive management of the other risk factors&#46;<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">26&#8211;30</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">In the years following the FDA directive&#44;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">10</span></a> studies have been published that shed light on the cardiovascular safety of 3 families of drugs&#58; dipeptidyl peptidase-4 inhibitors&#44; sodium-dependent glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Dipeptidyl peptidase-4 inhibitors reduce glucose levels by increasing insulin secretion and decreasing the secretion of glucose-dependent glucagon&#46; The group includes saxagliptin&#44; alogliptin&#44; and sitagliptin&#46; Their respective cardiovascular safety studies &#40;the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus &#91;SAVOR&#93;&#44;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">31</span></a> EXAMINE<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">32</span></a> and the Sitagliptin Cardiovascular Outcomes Study &#91;TECOS&#93;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">33</span></a>&#41; that included between 6000 and 16&#44;000 patients followed-up for 24&#8211;48 months showed their noninferiority in terms of reducing cardiovascular mortality&#44; infarction and stroke&#44; when compared with placebo&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Sodium-dependent glucose cotransporter 2 inhibitors reduce glucose reabsorption in the proximal renal tubules and decrease HbA1c levels&#44; blood pressure and weight&#44; with a low risk of hypoglycemia&#46; The group includes empagliflozine&#44; dapagliflozin and canagliflozin&#46; The Empagliflozin&#44; Cardiovascular Outcomes&#44; and Mortality in Type 2 Diabetes &#40;EMPA-REG-OUTCOME&#41; study<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">34</span></a> included 7020 patients randomized to 2 doses of empagliflozine or placebo&#44; with a mean follow-up of 3 years&#46; The drug significantly lowered all-cause death &#40;including cardiovascular&#41; and HF&#44; without affecting the infarction or stroke rates&#44; although there was a greater incidence of urinary tract infections&#46; The drug also showed a reduction in acute kidney injury and renal failure episodes&#46; Empagliflozine is the first NIAD that has shown a reduction in mortality&#44; although the patients in the EMPA-REG-OUTCOME study were frequently treated with other agents that reduced cardiovascular events&#44; such as statins and angiotensin-converting enzyme inhibitors&#46; A number of meta-analyses conducted with other drugs of this group have suggested a class effect&#44;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">35</span></a> which should be confirmed with safety studies for each of the drugs&#44; such as the Canagliflozin Cardiovascular Assessment Study&#44;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">36</span></a> which is still awaiting publication&#46;</p><p id="par0170" class="elsevierStylePara elsevierViewall">Glucagon-like peptide-1 receptor agonists are injectable drugs that increase insulin secretion and decrease the secretion of glucose-dependent glucagon&#46; These drugs increase satiety&#44; thereby promoting weight loss&#46; The group includes liraglutide and semaglutide&#46; The drugs are not available in the European Union&#44; and 2 studies have been published on their cardiovascular safety&#46; The Liraglutide Effect and Action in Diabetes&#58; Evaluation of Cardiovascular Outcome Results study included 9340 patients randomized to liraglutide or placebo&#44; with a follow-up of 3&#46;8 years&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">37</span></a> The study showed a significant reduction in total and cardiovascular mortality in the treatment group&#44; as well as a significant reduction in kidney damage&#44; with a tendency to decrease infarctions&#44; strokes and HF&#46; Another study&#44; the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes &#40;SUSTAIN-6&#41;&#44; included 3297 patients randomized to 2 doses of semaglutide or placebo&#44; with a follow-up of 2 years&#46;<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">38</span></a> In the treatment group&#44; there was no apparent reduction in death from cardiovascular causes or nonfatal infarction&#44; but there was a reduction in nonfatal stroke and nephropathy&#46; The use of semaglutide was associated with a significant increase in complicated retinopathy&#46; Lixisenatide &#40;another drug in the group&#41; did not lower the rate of recurrent events in patients with diabetes who had had a recent acute ischemic event&#46;<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">39</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Conclusions&#46; Future prospects</span><p id="par0175" class="elsevierStylePara elsevierViewall">From the above&#44; we can conclude the following&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1&#41;</span><p id="par0180" class="elsevierStylePara elsevierViewall">Despite the enormous repercussion of DM2&#44; studies designed to assess the benefit of NIADs for CVR are scarce&#44; and only the United Kingdom Prospective Diabetes Study&#44;<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">18</span></a> in its metformin branch&#44; has shown this benefit&#46; The most recent studies were safety studies and were designed to detect noninferiority&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">31&#8211;34&#44;36&#8211;38</span></a></p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2&#41;</span><p id="par0185" class="elsevierStylePara elsevierViewall">The available evidence indicates that the greatest reduction in CVR in DM2 is due to the use of statins and strict blood pressure control&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3&#41;</span><p id="par0190" class="elsevierStylePara elsevierViewall">Doubts remain about certain sulfonylureas &#40;glimepiride&#44; glibenclamide&#44; glipizide&#44; and tolbutamide&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">15</span></a> due to the lack of solid evidence on their cardiovascular benefit&#46; These doubts could influence research into new drugs&#44; if the new drugs are compared to drugs with dubious effect&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">40</span></a></p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4&#41;</span><p id="par0195" class="elsevierStylePara elsevierViewall">Empagliflozine&#44; liraglutide and semaglutide appear to reduce CVR&#44; a statement that should be prudent due to the following facts&#58; &#40;a&#41; studies are needed to demonstrate superiority in reducing cardiovascular events&#59; &#40;b&#41; we need to understand the mechanisms by which the benefits are produced and determine the potential class effects&#59; &#40;c&#41; follow-ups are still limited when we consider the disease&#39;s natural progression&#59; and &#40;d&#41; we need to demonstrate a benefit on microvascular disease&#46; Along these lines&#44; the possible deterioration in retinopathy observed with semaglutide should be analyzed in depth&#46;<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">38</span></a></p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5&#41;</span><p id="par0200" class="elsevierStylePara elsevierViewall">The residual risk for patients with DM2&#44; in other words&#44; the fact that they continue to experience events despite being adequately treated with available resources&#44; warrants long-term studies and drug combinations that&#44; as well as being safe&#44; provide various benefits&#46; Empagliflozine &#40;which lowered mortality and HF<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">34</span></a>&#41; and liraglutide &#40;which lowered myocardial infarction and stroke<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">37</span></a>&#41; could be examples&#46;</p></li></ul></p><p id="par0205" class="elsevierStylePara elsevierViewall">In any case&#44; these studies have repercussions on daily practice&#46; The first treatment step for DM2 should be metformin&#46; In light of the new evidence and until we have more solid data&#44; the second step should consist of the previously mentioned drugs that have demonstrated safety and a potential for benefits on survival&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Conflicts of interest</span><p id="par0210" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:9 [
        0 => array:3 [
          "identificador" => "xres932897"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec907305"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres932896"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec907304"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Background"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Trials with noninsulin antidiabetic drugs in type 2 diabetes mellitus"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Conclusions&#46; Future prospects"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Conflicts of interest"
        ]
        8 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2016-11-23"
    "fechaAceptado" => "2017-02-04"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec907305"
          "palabras" => array:3 [
            0 => "Diabetes mellitus"
            1 => "Cardiovascular risk"
            2 => "Oral diabetes drugs"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec907304"
          "palabras" => array:3 [
            0 => "Diabetes mellitus"
            1 => "Riesgo cardiovascular"
            2 => "Antidiab&#233;ticos orales"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Non insulin antidiabetic drugs are widely used in patients with type 2 diabetes&#46; However&#44; the drugs&#8217; effect in terms of reducing cardiovascular risk has been the subject of controversy&#46; In 2008&#44; based on the evidence of cardiovascular risk resulting from the use of a number of non insulin antidiabetic drugs&#44; the US Food and Drug Administration published directives on the need to perform cardiovascular safety studies&#46; These directives have helped obtain more evidence&#44; such that at present there are 2 families of drugs that can reduce cardiovascular risk&#46; These recent data have helped us add the reduction of cardiovascular morbidity and mortality to the objective of controlling blood glucose&#46; Nevertheless&#44; research continues with the development of new long-term studies&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Los antidiab&#233;ticos no insul&#237;nicos son f&#225;rmacos de uso muy extendido en los pacientes con diabetes tipo 2&#44; cuyo efecto sobre la reducci&#243;n del riesgo cardiovascular ha sido objeto de controversia&#46; En el a&#241;o 2008&#44; ante la evidencia del riesgo cardiovascular derivado del uso de algunos antidiab&#233;ticos no insul&#237;nicos&#44; la <span class="elsevierStyleItalic">Food and Drug Administration</span> americana public&#243; una directriz sobre la necesidad de realizar estudios de seguridad cardiovascular&#46; Ello ha contribuido a disponer de m&#225;s evidencia&#44; de manera que en el momento actual existen dos familias de f&#225;rmacos que podr&#237;an reducir el riesgo cardiovascular&#46; Estos datos recientes nos permiten a&#241;adir&#44; al objetivo de controlar la glucemia&#44; el de reducir la morbimortalidad cardiovascular&#46; No obstante&#44; la investigaci&#243;n contin&#250;a con el desarrollo de nuevos estudios a largo plazo&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Garc&#237;a-Lled&#243; A&#44; de Santiago-Nocito AM&#44; de Abajo FJ&#46; Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#58; hechos y promesas&#46; Rev Clin Esp&#46; 2017&#59;217&#58;473&#8211;477&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Source</span>&#58; U&#46;S&#46; Department of Health and Human Services&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">10</span></a></p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">For studies with new designs</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>For phase 2 and 3 studies&#44; there should be an independent prospective adjudication committee for cardiovascular events&#46; The minimum cardiovascular events to be recorded are defined&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Phase 2 and 3 studies should include patients with high cardiovascular risk&#44; long-standing diabetes&#44; advanced age and kidney damage&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>A longer duration is proposed for safety studies &#40;at least 2 years&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Phase 2 and 3 studies should be designed to facilitate their subsequent inclusion in a meta-analysis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The sponsors should deliver a protocol that describes the statistical methods of the proposed meta-analyses&#46; Recommendations are made on the types of studies and identifiers for variables to be included&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The differences and similarities of the events by subgroup should be examined&#44; when possible&#44; indicating as examples sex&#44; race and age&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">For completed studies&#44; before submitting them for evaluation</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The statistical margins for the confidence interval are narrowed in the noninferiority studies regarding cardiovascular events&#46; When it is not possible to demonstrate them with meta-analyses&#44; new studies should be performed&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>If the premarketing request shows clinical data outside the previous demands but within less demanding predefined ranges and the overall risk&#8211;benefit analysis supports the approval of the drug&#44; a specific study may be requested to demonstrate the safety adjusted to the new required limits&#44; once the drug has been marketed&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>The characteristics these studies must have for their evaluation and inclusion in meta-analyses are defined&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1576665.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Summary of the food and drug administration directives for the assessment of cardiovascular risk in new antidiabetic therapies&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:40 [
            0 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalence of diabetes mellitus and impaired glucose regulation in Spain&#58; the Di&#64;bet&#46;es Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Soriguer"
                            1 => "A&#46; Goday"
                            2 => "A&#46; Bosch-Comas"
                            3 => "E&#46; Bordi&#250;"
                            4 => "A&#46; Calle-Pascual"
                            5 => "R&#46; Carmena"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00125-011-2336-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetologia"
                        "fecha" => "2012"
                        "volumen" => "55"
                        "paginaInicial" => "88"
                        "paginaFinal" => "93"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21987347"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global prevalence of diabetes&#46; Estimates for the year 2000 and projections for 2030"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46; Wild"
                            1 => "G&#46; Roglic"
                            2 => "A&#46; Green"
                            3 => "R&#46; Sicree"
                            4 => "H&#46; King"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Diabetes Care"
                        "fecha" => "2004"
                        "volumen" => "27"
                        "paginaInicial" => "1047"
                        "paginaFinal" => "1053"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15111519"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Seguridad cardiovascular de los antidiab&#233;ticos no insul&#237;nicos&#46; Posicionamiento cient&#237;fico Semergen"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;A&#46; Prieto"
                            1 => "J&#46;M&#46; Comas-Samper"
                            2 => "C&#46; Escobar-Cervantes"
                            3 => "V&#46; Gasull-Molinera"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semerg.2014.04.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semergen"
                        "fecha" => "2014"
                        "volumen" => "40"
                        "paginaInicial" => "261"
                        "paginaFinal" => "273"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24882393"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diabetes mellitus&#44; fasting glucose&#44; and risk of cause-specific death"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;R&#46; Seshasai"
                            1 => "S&#46; Kaptoge"
                            2 => "A&#46; Thompson"
                            3 => "E&#46; di Angelantonio"
                            4 => "P&#46; Gao"
                            5 => "N&#46; Sarwar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1008862"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2011"
                        "volumen" => "364"
                        "paginaInicial" => "829"
                        "paginaFinal" => "841"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21366474"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relaciones epidemiol&#243;gicas de la enfermedad arterioscler&#243;tica entre los diferentes territorios vasculares"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "W&#46;B&#46; Kannel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:5 [
                        "titulo" => "Aterosclerosis y enfermedad coronaria"
                        "paginaInicial" => "1691"
                        "paginaFinal" => "1698"
                        "edicion" => "1&#46;&#170; ed"
                        "serieFecha" => "1997"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalencia de angina estable en Espa&#241;a&#46; Resultados del estudio OFRECE"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Alonso"
                            1 => "J&#46; Mu&#241;iz"
                            2 => "J&#46;J&#46; G&#243;mez-Doblas"
                            3 => "G&#46; Rodr&#237;guez-Roca"
                            4 => "J&#46;M&#46; Lobos"
                            5 => "G&#46; Permanyer-Miralda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rec.2014.09.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Esp Cardiol"
                        "fecha" => "2015"
                        "volumen" => "68"
                        "paginaInicial" => "691"
                        "paginaFinal" => "699"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25697076"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acute myocardial infarction in diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46;W&#46; Nesto"
                            1 => "S&#46; Zarich"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "1998"
                        "volumen" => "97"
                        "paginaInicial" => "12"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9443424"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46; Nissen"
                            1 => "K&#46; Wolsky"
                            2 => "E&#46;J&#46; Topol"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.294.20.joc50147"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2005"
                        "volumen" => "294"
                        "paginaInicial" => "2581"
                        "paginaFinal" => "2586"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16239637"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46; Nissen"
                            1 => "K&#46; Wolsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa072761"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2007"
                        "volumen" => "356"
                        "paginaInicial" => "2457"
                        "paginaFinal" => "2471"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17517853"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "U&#46;S&#46; Department of Health and Human Services&#46; Food and Drug Administration&#46; Center for Drug Evaluation and Research &#40;CDER&#41;&#46; Guidance for Industry Diabetes Mellitus&#46; Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 Diabetes&#46; December 2008&#46; &#91;consulted 12 Nov 2016&#93;&#46; http&#58;&#47;&#47;www&#46;fda&#46;gov&#47;downloads&#47;drugs&#47;guidancecomplianceregulatoryinformation&#47;guidances&#47;ucm071627&#46;pdf&#46;"
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Impact of FDA guidance for developing diabetes drugs on trial design&#58; from policy to practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;A&#46; Bethel"
                            1 => "H&#46; Sourij"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11886-011-0229-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Cardiol Rep"
                        "fecha" => "2012"
                        "volumen" => "14"
                        "paginaInicial" => "59"
                        "paginaFinal" => "69"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22094711"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes&#58; II&#46; Mortality results"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "University Group Diabetes Program Research Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Diabetes"
                        "fecha" => "1970"
                        "volumen" => "19"
                        "paginaInicial" => "785"
                        "paginaFinal" => "830"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The UGDP controversy&#58; thirty-four years of contentious ambiguity laid to rest"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "T&#46;B&#46; Schwartz"
                            1 => "C&#46;L&#46; Meinert"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Perspect Biol Med"
                        "fecha" => "2004"
                        "volumen" => "47"
                        "paginaInicial" => "564"
                        "paginaFinal" => "574"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15467178"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium&#46; Two paradoxes revisited"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46;C&#46; Cleveland Jr&#46;"
                            1 => "D&#46;R&#46; Meldrum"
                            2 => "B&#46;S&#46; Cain"
                            3 => "A&#46; Banerjee"
                            4 => "A&#46;H&#46; Harken"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "1997"
                        "volumen" => "96"
                        "paginaInicial" => "29"
                        "paginaFinal" => "32"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9236412"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes&#44; with or without a previous myocardial infarction&#58; a nationwide study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;K&#46; Schramm"
                            1 => "G&#46;H&#46; Gislason"
                            2 => "A&#46; Vaag"
                            3 => "J&#46;N&#46; Rasmussen"
                            4 => "F&#46; Folke"
                            5 => "M&#46;L&#46; Hansen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehr077"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2011"
                        "volumen" => "32"
                        "paginaInicial" => "1900"
                        "paginaFinal" => "1908"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21471135"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "Diabetes Control&#44; Complications Trial Research Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM199309303291401"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1993"
                        "volumen" => "329"
                        "paginaInicial" => "977"
                        "paginaFinal" => "986"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8366922"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "P&#46; Reichard"
                            1 => "B&#46;Y&#46; Nilsson"
                            2 => "V&#46; Rosenqvist"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM199307293290502"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1993"
                        "volumen" => "329"
                        "paginaInicial" => "304"
                        "paginaFinal" => "309"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8147960"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "UK Prospective Diabetes Study Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "1998"
                        "volumen" => "352"
                        "paginaInicial" => "837"
                        "paginaFinal" => "853"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9742976"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of intensive blood glucose control policy with metformin on complications in type 2 diabetes patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "UK Prospective Diabetes Study Group"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "1998"
                        "volumen" => "352"
                        "paginaInicial" => "854"
                        "paginaFinal" => "865"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9742977"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "10-Year follow-up of intensive glucose control in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Colman"
                            1 => "S&#46;K&#46; Paul"
                            2 => "M&#46;A&#46; Bethel"
                            3 => "D&#46;R&#46; Matthews"
                            4 => "H&#46;A&#46; Neil"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0806470"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "359"
                        "paginaInicial" => "1577"
                        "paginaFinal" => "1589"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18784090"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "PROactive investigators&#46; Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study &#40;PROspective pioglitAzone Clinical Trial in macro-Vascular Events&#41;&#58; a randomised controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;A&#46; Dormandy"
                            1 => "B&#46; Charbonnel"
                            2 => "D&#46;J&#46; Eckland"
                            3 => "E&#46; Erdmann"
                            4 => "M&#46; Massi-Benedetti"
                            5 => "I&#46;K&#46; Moules"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(05)67528-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2005"
                        "volumen" => "366"
                        "paginaInicial" => "1279"
                        "paginaFinal" => "1289"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16214598"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes &#40;RECORD&#41;&#58; a multicentre&#44; randomised&#44; open-label trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46;D&#46; Home"
                            1 => "S&#46;J&#46; Pocock"
                            2 => "H&#46; Beck-Nielsen"
                            3 => "P&#46;S&#46; Curtis"
                            4 => "R&#46; Gomis"
                            5 => "M&#46; Hanefeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(09)60953-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2009"
                        "volumen" => "373"
                        "paginaInicial" => "2125"
                        "paginaFinal" => "2135"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19501900"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Patel"
                            1 => "S&#46; MacMahon"
                            2 => "J&#46; Chalmers"
                            3 => "B&#46; Neal"
                            4 => "L&#46; Billot"
                            5 => "M&#46; Woodward"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0802987"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "2560"
                        "paginaFinal" => "2572"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18539916"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of intensive glucose lowering in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;C&#46; Gerstein"
                            1 => "M&#46;E&#46; Miller"
                            2 => "R&#46;P&#46; Byington"
                            3 => "D&#46;C&#46; Goff Jr&#46;"
                            4 => "J&#46;T&#46; Bigger"
                            5 => "J&#46;B&#46; Buse"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0802743"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "2545"
                        "paginaFinal" => "2559"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18539917"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Glucose control and vascular complications in veterans with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "W&#46; Duckworth"
                            1 => "C&#46; Abraira"
                            2 => "T&#46; Moritz"
                            3 => "D&#46; Reda"
                            4 => "N&#46; Emanuele"
                            5 => "P&#46; Reaven"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0808431"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2009"
                        "volumen" => "360"
                        "paginaInicial" => "129"
                        "paginaFinal" => "139"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19092145"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of a multifactorial intervention on mortality in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "P&#46; Gaede"
                            1 => "H&#46; Lund-Andersen"
                            2 => "H&#46;H&#46; Parving"
                            3 => "O&#46; Pedersen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa0706245"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2008"
                        "volumen" => "358"
                        "paginaInicial" => "580"
                        "paginaFinal" => "591"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18256393"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study &#40;CARDS&#41;&#58; multicentre randomised placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;M&#46; Colhoun"
                            1 => "D&#46;J&#46; Betteridge"
                            2 => "P&#46;N&#46; Durrington"
                            3 => "G&#46;A&#46; Hitman"
                            4 => "H&#46;A&#46; Neil"
                            5 => "S&#46;J&#46; Livingstone"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(04)16895-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2004"
                        "volumen" => "364"
                        "paginaInicial" => "685"
                        "paginaFinal" => "696"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15325833"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of cholesterol-lowering treatment&#58; prospective meta-analysis of data from 90&#44;056 participants in 14 randomised trials of statins"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Baigent"
                            1 => "A&#46; Keech"
                            2 => "P&#46;M&#46; Kearney"
                            3 => "L&#46; Blackwell"
                            4 => "G&#46; Buck"
                            5 => "C&#46; Pollicino"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(05)67394-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2005"
                        "volumen" => "366"
                        "paginaInicial" => "1267"
                        "paginaFinal" => "1278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16214597"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Blood pressure lowering in type 2 diabetes&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C&#46;A&#46; Emdin"
                            1 => "K&#46; Rahimi"
                            2 => "B&#46; Neal"
                            3 => "T&#46; Callender"
                            4 => "V&#46; Perkovic"
                            5 => "A&#46; Patel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.2014.18574"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2015"
                        "volumen" => "313"
                        "paginaInicial" => "603"
                        "paginaFinal" => "615"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25668264"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "European Guidelines on cardiovascular disease prevention in clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "The sixth joint task force of the European Society of Cardiology&#44; other societies on cardiovascular disease prevention in clinical practice"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehw106"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2016"
                        "volumen" => "37"
                        "paginaInicial" => "2315"
                        "paginaFinal" => "2323"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27222591"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "SAVOR-TIMI 53 Steering Committee and Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46;M&#46; Scirica"
                            1 => "D&#46;L&#46; Bhatt"
                            2 => "E&#46; Braunwald"
                            3 => "P&#46;G&#46; Steg"
                            4 => "J&#46; Davidson"
                            5 => "B&#46; Hirshberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1307684"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "369"
                        "paginaInicial" => "1317"
                        "paginaFinal" => "1326"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23992601"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alogliptin after acute coronary syndrome in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "EXAMINE Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "W&#46;B&#46; White"
                            1 => "C&#46;P&#46; Cannon"
                            2 => "S&#46;R&#46; Heller"
                            3 => "S&#46;E&#46; Nissen"
                            4 => "R&#46;M&#46; Bergenstal"
                            5 => "G&#46;L&#46; Bakris"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1305889"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "369"
                        "paginaInicial" => "1327"
                        "paginaFinal" => "1335"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23992602"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;B&#46; Green"
                            1 => "M&#46;A&#46; Bethel"
                            2 => "P&#46;W&#46; Armstrong"
                            3 => "J&#46;B&#46; Buse"
                            4 => "S&#46;S&#46; Engel"
                            5 => "J&#46; Garg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1501352"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "232"
                        "paginaFinal" => "242"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26052984"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Empagliflozin&#44; cardiovascular outcomes&#44; and mortality in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "EMPA-REG OUTCOME Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Zinman"
                            1 => "C&#46; Wanner"
                            2 => "J&#46;M&#46; Lachin"
                            3 => "D&#46; Fitchett"
                            4 => "E&#46; Bluhmki"
                            5 => "S&#46; Hantel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "2117"
                        "paginaFinal" => "2128"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of SGLT-2 inhibitors on mortality and cardiovascular events&#58; a comprehensive meta-analysis of randomized controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46; Monami"
                            1 => "I&#46; Dicembrini"
                            2 => "E&#46; Mannucci"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00592-016-0892-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Diabetol"
                        "fecha" => "2017"
                        "volumen" => "54"
                        "paginaInicial" => "19"
                        "paginaFinal" => "36"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27488726"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rationale&#44; design&#44; and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study &#40;CANVAS&#41;&#58; a randomized placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Neal"
                            1 => "V&#46; Perkovic"
                            2 => "D&#46; de Zeeuw"
                            3 => "K&#46;W&#46; Mahaffey"
                            4 => "G&#46; Fulcher"
                            5 => "P&#46; Stein"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ahj.2013.05.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am Heart J"
                        "fecha" => "2013"
                        "volumen" => "166"
                        "paginaInicial" => "217"
                        "paginaFinal" => "223"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23895803"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Liraglutide and cardiovascular outcomes in type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;P&#46; Marso"
                            1 => "G&#46;H&#46; Daniels"
                            2 => "K&#46; Brown-Frandsen"
                            3 => "P&#46; Kristensen"
                            4 => "J&#46;F&#46; Mann"
                            5 => "M&#46;A&#46; Nauck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1603827"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2016"
                        "volumen" => "375"
                        "paginaInicial" => "311"
                        "paginaFinal" => "322"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27295427"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;P&#46; Marso"
                            1 => "S&#46;C&#46; Bain"
                            2 => "A&#46; Consoli"
                            3 => "F&#46;G&#46; Eliaschewitz"
                            4 => "E&#46; J&#243;dar"
                            5 => "L&#46;A&#46; Leiter"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1607141"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2016"
                        "volumen" => "375"
                        "paginaInicial" => "1834"
                        "paginaFinal" => "1844"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27633186"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lixisenatide in patients with type 2 diabetes and acute coronary s&#237;ndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;A&#46; Pfeffer"
                            1 => "B&#46; Claggett"
                            2 => "R&#46; Diaz"
                            3 => "K&#46; Dickstein"
                            4 => "H&#46;C&#46; Gerstein"
                            5 => "L&#46;V&#46; K&#248;ber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1509225"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2015"
                        "volumen" => "373"
                        "paginaInicial" => "2247"
                        "paginaFinal" => "2257"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26630143"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone&#58; impact on cardiovascular events&#46; A randomized controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "O&#46; Vaccaro"
                            1 => "M&#46; Masulli"
                            2 => "E&#46; Bonora"
                            3 => "S&#46; Del Prato"
                            4 => "C&#46;B&#46; Giorda"
                            5 => "A&#46;P&#46; Maggioni"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.numecd.2012.09.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nutr Metab Cardiovasc Dis"
                        "fecha" => "2012"
                        "volumen" => "22"
                        "paginaInicial" => "997"
                        "paginaFinal" => "1006"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23063367"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/22548874/0000021700000008/v1_201710301109/S2254887417300358/v1_201710301109/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "48740"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Reviews"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/22548874/0000021700000008/v1_201710301109/S2254887417300358/v1_201710301109/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887417300358?idApp=WRCEE"
]
Article information
ISSN: 22548874
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2023 March 3 4 7
2017 November 0 2 2
2017 October 0 3 3
2017 May 0 1 1

Follow this link to access the full text of the article

Idiomas
Revista Clínica Española (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?